Background: Intravenous dosing is generally recognized to be the only effective means of maintaining a high concentration of vitamin C in the plasma. High dosing of vitamin C has been reported to be beneficial in, among other things, improving the quality of life as well as survival time of patients with terminal cancer. There is a paucity of information on the depletion of vitamin C in plasma at the high dosing regimen.
INTRODUCTION
Vitamin C (syn� ascorbic acid) is an essential micronutrient which is involved in biological and biochemical functions in humans� This vitamin could not be synthesized in situ by humans� The principal sources for humans are either routine consumption of fruits and vegetables, or through on-purpose oral or intravenous intake of vitamin C supplement� The tolerable upper intake level of vitamin C, by oral means, is generally cited to be in the range of 2,000 mg per day for adults (1)� This level corresponds approximately to the optimum daily intake first advocated by Pauling (2) nearly 4 decades ago� Some of the adverse side effects of chronic high (oral) dosing have been observed to be diarrhea and hyperoxaluria (3)� The physiological barrier to oral administration to attain a higher concentration in the plasma is due to intestinal absorption and renal excretion of vitamin C (4)� Indeed, if the renal function was impaired, a high concentration of vitamin C (as administered orally) in the plasma can be expected (5)� Padayatty et al� (6) have found vitamin C concentration in the plasma to vary substantially with the route of administration� The safe chronic intake of as much as 40 grams per day has been reported previously for the treatment of various viral and bacterial infections (2)� The use of very high doses of vitamin C to treat terminal cancer patients was first proposed in the late 1950s� Cameron and Pauling (7, 8) reported the significant extension of life of cohorts of terminal cancer patients by several hundred days� The science of vitamin C treatment of cancer patients have not been investigated actively for the past few decades because neither the vitamin C molecule nor the therapeutic use of vitamin C is patentable� The interest of vitamin C therapy has however been renewed recently with the publication of several notable case studies in which vitamin C-treated cancer patients were reported to live an additional 3 to 10 years, after their first prognosis of the final stage of terminal cancer (9-15)� Present knowledge suggests that Vitamin C is transported readily from the circulating plasma into malignant cells to mediate the subsequent formation of cytotoxic H 2 O 2 (16-18)� In in-vitro studies, non-malignant cells were found to be not affected by such vitamin C treatment (17, 19-24)� Duconge et al� (25) have recently reviewed current state of knowledge pharmacokinetics of vitamin C from both oral and intravenous perspectives� There is no means available presently to the medical practitioners for setting the frequency of intravenous administration of high doses of vitamin C� We have undertaken this investigation to estimate the depletion time of intravenous administration of high doses of vitamin C in plasma�
MeThODs
The primary human-subject data reported by Levine et al� (26) and Riordan et al� (27) are used in this analysis� Chemical kinetic studies could be used to deduce the underlying mechanism involved in the transport of vitamin C from the plasma into the cell structure (28-29)� First-order reactions are the most common� A firstorder reaction is defined as one for which, at a given temperature, the rate of the reaction depends only on the first power of the concentration of a single reacting species� In the case of vitamin C concentration in the plasma, the kinetic study began with the assumption that the reaction(s) causing vitamin C decrease is essentially first-order� The classical first-order reaction can be expressed as 
...(2)
A plot of log c versus t would yield a straight line, of which the slope is the rate constant value k�
ResUlTs
As given in Figure 1 and 2, Levine et al� (26) have reported that both oral and intravenous dosing of Vitamin C would reach rapidly similar background value of about 80 μM, at the two example doses of 200 mg and 1,250 mg of Vitamin C� Healthy volunteers were the test subjects� In this study, this limiting value, i�e�, 80 μM, was used as the terminal value for the selection of experimental data for the estimation of the first-order rate constant� It may be noted in Figure 2 , the maximum value reached with an oral intake of 1,250 mg of Vitamin C was approximately 150 μM, more than 10 times less than the threshold pharmacological concentration noted in in vitro studies of Chen et al� (17)� In the data set of Riordan et al. (27) , the experiments were made under a repeat dosing regimen, i�e�, injection of vitamin C was made at pre-set intervals, on cancer patients� The plasma vitamin C level was never allowed to reach the background value in their study� Figure 3 shows the estimation of first-order rate constant, using the published data of Levine et al� (26) and Riordan et al� (27)� A cursory review of the slope of the four curves suggested that the data might be pooled to provide a single average rate constant� The specific calculation involves the use of the individual rate constant (from Figure 3) and the application of an arbitrary common initial concentration (viz�, 60,000 mg vitamin C)� As given in Figure 4 , the degree of correlation of the best-fit curve was generally satisfactory� The estimated rate constant could be inserted into equation (2) 
DIsCUssION
It is interesting to note that a single rate constant is essentially applicable to describe the rate of depletion of vitamin C from the plasma of healthy volunteers as well as for cancer patients, over the range of intravenous administration of 200 mg to 60,000 mg� This observation also suggests that the transport of vitamin C from the plasma across the cell (17) has found the effective pharmacologic concentration to be about 2,000 μM vitamin C� If this threshold concentration in the plasma was required for therapeutic activity in human patients, then the time interval required for repeated injection of 60,000 mg vitamin C could be calculated to be about every 8 hours�
CONClUsION
Despite the limited availability of experimental data, we have developed a protocol for the estimation of depletion time of intravenously-administered vitamin C from the plasma� This preliminary assessment could now provide the medical professionals with a means to set the time interval of repeated dosing of vitamin C to maintain a threshold value for, among other things, the therapeutic treatment of patients afflicted with cancer�
